These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31853424)

  • 1. Systematic Screening, Rational Development, and Initial Optimization of Efficacious RNA Silencing Agents for Human Rod Opsin Therapeutics.
    Yau EH; Taggart RT; Zuber M; Trujillo AJ; Fayazi ZS; Butler MC; Sheflin LG; Breen JB; Yu D; Sullivan JM
    Transl Vis Sci Technol; 2019 Nov; 8(6):28. PubMed ID: 31853424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.
    Yau EH; Butler MC; Sullivan JM
    Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.
    Abdelmaksoud HE; Yau EH; Zuker M; Sullivan JM
    Exp Eye Res; 2009 May; 88(5):859-79. PubMed ID: 19094986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid, cell-based toxicity screen of potentially therapeutic post-transcriptional gene silencing agents.
    Kolniak TA; Sullivan JM
    Exp Eye Res; 2011 May; 92(5):328-37. PubMed ID: 21256844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Pathogenic Variations in the Human Rhodopsin Gene (hRHO) on the Predicted Accessibility for a Lead Candidate Ribozyme.
    Froebel BR; Trujillo AJ; Sullivan JM
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3576-3591. PubMed ID: 28715844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice.
    Liu J; Timmers AM; Lewin AS; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3836-44. PubMed ID: 16186371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.
    Sullivan JM; Yau EH; Kolniak TA; Sheflin LG; Taggart RT; Abdelmaksoud HE
    J Ophthalmol; 2011; 2011():531380. PubMed ID: 21785698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Discovery with Potential to Revitalize Hammerhead Ribozyme Therapeutics for Treatment of Inherited Retinal Degenerations.
    Trujillo AJ; Myers JM; Fayazi ZS; Butler MC; Sullivan JM
    Adv Exp Med Biol; 2019; 1185():119-124. PubMed ID: 31884599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity.
    Khvorova A; Lescoute A; Westhof E; Jayasena SD
    Nat Struct Biol; 2003 Sep; 10(9):708-12. PubMed ID: 12881719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Automated High-Throughput Fluorescence In Situ Hybridization (FISH) Assay Platform for Use in the Identification and Optimization of siRNA-Based Therapeutics.
    Dou HH; Mallari R; Pipathsouk A; Das A; Lo MC
    SLAS Discov; 2021 Feb; 26(2):281-291. PubMed ID: 33016168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach.
    Gorbatyuk MS; Pang JJ; Thomas J; Hauswirth WW; Lewin AS
    Mol Vis; 2005 Aug; 11():648-56. PubMed ID: 16145542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent knockdown of the X RNA of hepatitis B by a novel chimeric siRNA-ribozyme construct and modulation of intracellular target RNA by selectively disabled mutants.
    Gupta N; Bano AS; Sharma Y; Banerjea AC
    Oligonucleotides; 2008 Sep; 18(3):225-33. PubMed ID: 18707539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mislocalization and degradation of human P23H-rhodopsin-GFP in a knockin mouse model of retinitis pigmentosa.
    Price BA; Sandoval IM; Chan F; Simons DL; Wu SM; Wensel TG; Wilson JH
    Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9728-36. PubMed ID: 22110080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship of pseudoknot-type hammerhead ribozyme reveals key structural elements for enhanced catalytic activity
    Yamada M; Tanaka Y
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):245-257. PubMed ID: 31578927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.
    Sullivan JM; Yau EH; Taggart RT; Butler MC; Kolniak TA
    Vision Res; 2008 Feb; 48(3):453-69. PubMed ID: 17976683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.
    Rao DD; Maples PB; Senzer N; Kumar P; Wang Z; Pappen BO; Yu Y; Haddock C; Jay C; Phadke AP; Chen S; Kuhn J; Dylewski D; Scott S; Monsma D; Webb C; Tong A; Shanahan D; Nemunaitis J
    Cancer Gene Ther; 2010 Nov; 17(11):780-91. PubMed ID: 20596090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of putative miRNA binding sites and mRNA 3' ends as targets for siRNA-mediated gene knockdown.
    Bergauer T; Krueger U; Lader E; Pilk S; Wolter I; Bielke W
    Oligonucleotides; 2009 Mar; 19(1):41-52. PubMed ID: 19196098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.